الفهرس الالي لمكتبة كلية الطب
Détail de l'auteur
Auteur Bradwell AR |
Documents disponibles écrits par cet auteur
Affiner la recherche Interroger des sources externes
Serum free light chain analysis / Bradwell AR
Titre : Serum free light chain analysis Type de document : texte imprimé Auteurs : Bradwell AR, Auteur Mention d'édition : 4 ème édition Editeur : The Binding site Année de publication : 2006 Importance : 285p. Présentation : ill. Format : 23-16 cm. Accompagnement : CD ISBN/ISSN/EAN : 978-0-7044-2529-3 Langues : Français (fre) Résumé : There is great interest in using serum free light chain measurements alongside serum protein electrophoresis o screen symptomatic patients for monoclonal gammopathies. The strategy is more sensitive than testing for Bence Jones proteinuria: both simpler and clinically more accurate, Many centres are now using the test in this manner, leading to improvements in patient diagnosis and management. Support for this approach is seen in the emerging International Guidelines for treating patients with multiple myeloma and AI. amyloidosis. Uniform Response criteria have been defined, and patients previously thought to have nonsecretory disease can now enter clinical trials. The full impact of the Free light chains as fast response markers in therapy is yet to be realized. But, in some centres, failure of serum free light chain concentrations to fall rapidly following treatment alterations is interpreted as therapeutic failure. Drug doses of regimens are altered accordingly and ineffective chemotherapy terminated. Serum free light chain analysis [texte imprimé] / Bradwell AR, Auteur . - 4 ème édition . - [S.l.] : The Binding site, 2006 . - 285p. : ill. ; 23-16 cm. + CD.
ISBN : 978-0-7044-2529-3
Langues : Français (fre)
Résumé : There is great interest in using serum free light chain measurements alongside serum protein electrophoresis o screen symptomatic patients for monoclonal gammopathies. The strategy is more sensitive than testing for Bence Jones proteinuria: both simpler and clinically more accurate, Many centres are now using the test in this manner, leading to improvements in patient diagnosis and management. Support for this approach is seen in the emerging International Guidelines for treating patients with multiple myeloma and AI. amyloidosis. Uniform Response criteria have been defined, and patients previously thought to have nonsecretory disease can now enter clinical trials. The full impact of the Free light chains as fast response markers in therapy is yet to be realized. But, in some centres, failure of serum free light chain concentrations to fall rapidly following treatment alterations is interpreted as therapeutic failure. Drug doses of regimens are altered accordingly and ineffective chemotherapy terminated. Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité BFM-8952 616.7-41.1 Ouvrage Faculté de Médecine 600 - Technologie (Sciences appliquées) Exclu du prêt